Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Trump Buys SpaceX Shares After Record IPO 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Tesla Raises Cybertruck Prices by $5,000 in US 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Nvidia Options Price in $280 Billion Earnings Swing 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Add as a preferred source on Google
NEWARK, Calif., May 01, 2018 -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Tuesday, May 8, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2018 and to provide a business update.
Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13678369. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof of concept in PBC. CymaBay is currently planning to advance development of seladelpar into Phase 3 for PBC and Phase 2 for NASH.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
[email protected]
